Cat. No.: HY-150761

MY-875

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

MY-875 is a competitive microtubulin polymerization inhibitor with an IC₅₀ value of 0.92 μM. MY-875 inhibits microtubulin polymerization by targeting colchicine binding sites and activates the Hippo pathway. MY-875 induces apoptosis and has anticancer activity.

For research use only. We do not sell to patients.

Purity: 99.56%
Formula: C₂₁H₂₅NO₆
Molecular Weight:387.43

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

MY-875 Chemical Structure

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.059 μM Compound: I-33; MY-875	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
DU-145	IC₅₀	0.081 μM Compound: I-33; MY-875	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
ECa-109 cell line	IC₅₀	0.085 μM Compound: I-33; MY-875	Antiproliferative activity against human EC109 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human EC109 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
GES1	IC₅₀	768 nM Compound: I-33; MY-875	Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 35834904]
HCT-116	IC₅₀	0.054 μM Compound: 4	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36940611]
HCT-116	IC₅₀	0.055 μM Compound: I-33; MY-875	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
HGC-27	IC₅₀	0.033 μM Compound: I-33; MY-875	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
Huh-7	IC₅₀	0.06 μM Compound: I-33; MY-875	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
HUVEC	IC₅₀	48470 nM Compound: I-33; MY-875	Cytotoxicity against human HUVEC cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HUVEC cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 35834904]
KYSE-450	IC₅₀	0.062 μM Compound: 4	Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36940611]
KYSE-450	IC₅₀	0.067 μM Compound: I-33; MY-875	Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
MCF7	IC₅₀	0.067 μM Compound: I-33; MY-875	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
MGC-803	IC₅₀	0.027 μM Compound: I-33; MY-875	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
MGC-803	IC₅₀	0.028 μM Compound: 4	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36940611]
NCI-H520	IC₅₀	0.052 μM Compound: I-33; MY-875	Antiproliferative activity against human NCI-H520 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H520 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
PC-3	IC₅₀	0.055 μM Compound: I-33; MY-875	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
SGC-7901	IC₅₀	0.025 μM Compound: I-33; MY-875	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
SMMC-7721	IC₅₀	0.043 μM Compound: I-33; MY-875	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]
TE-1	IC₅₀	0.094 μM Compound: I-33; MY-875	Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35834904]

In Vitro

MY-875 (0-80 μM, 48 h) has significant anti-proliferative activity against cancer cells^[1].
MY-875 (1-10 μM) can inhibit microtubule protein polymerization with an IC₅₀ value of 0.92 μM while inhibiting alkylation of β-tubulin and the formation of EBI-β-tubulin adduct bands in a dose-dependent manner^[1].
MY-875 (0-45 nM, 48 h) can induce the phosphorylation state of MST (Ste20-like kinases) and LATS (large tumor suppressor kinases), leading to YAP (Yes-associated protein) degradation in a dose-dependent manner^[1].
MY-875 (0-45 nM, 24 h) significantly inhibits cell colony-forming ability, arrests cells in the G2/M phase and induces cell apoptosis in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MGC-803, HCT-116, KYSE450, HGC-27, SGC-7901cell lines
Concentration:

0-80 μM
Incubation Time:

48 hours
Result:

Inhibited the proliferation of MGC-803, HCT-116, KYSE450, HGC-27 and SGC-7901 cells with the IC₅₀ values of 0.027, 0.055, 0.067, 0.033 and 0.025 μM, respectively.
Showed strong inhibitory effect on other tumor cell lines with the IC₅₀ values less than 0.1 μM, such as DU145, A549, MCF-7, etc.

Cell Cycle Analysis^[1]

Cell Line:

MGC-803, SGC-7901 cell lines
Concentration:

0-45 nM
Incubation Time:

24 hours
Result:

Increased the percentage of cells in G2/M phase from 19.38% to 76.97% in MGC-803 cells and from 7.04% to 80.89% in SGC-7901 cells, respectively at 45 nM.

Apoptosis Analysis^[1]

Cell Line:

MGC-803, SGC-7901 cell lines
Concentration:

0-45 nM
Incubation Time:

48 hours
Result:

Induced apoptotic cells from 21.96% to 76.08% in MGC-803 cells and from 9.28% to 63.51% in SGC-7901 cells, respectively at 45 nM.
Reduced expression of anti-apoptotic proteins c-IAP1, Bcl-xL and Mcl-1.

Chemical Information

Appearance Solid
Molecular Weight 387.43
Formula C₂₁H₂₅NO₆
Color White to off-white
SMILES

COC1=CC(N(C(/C=C/C)=O)CC2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Inflammation

Caveolin-2 Knockdown Alleviated Sepsis-induced Acute Lung Injury Via Promoting Macrophage M2 Polarization and Inhibiting Apoptosis by Hippo Signaling Pathway. [Abstract]

2026 Jan 19;49(1):66. PMID: 41549180

Solvent & Solubility

In Vitro:

DMSO : ≥ 250 mg/mL (645.28 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5811 mL

12.9056 mL

25.8111 mL

5 mM

0.5162 mL

2.5811 mL

5.1622 mL

10 mM

0.2581 mL

1.2906 mL

2.5811 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Jian Song, et al. Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. Eur J Med Chem. 2022 Jul 7;240:114583. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5811 mL	12.9056 mL	25.8111 mL	64.5278 mL
	5 mM	0.5162 mL	2.5811 mL	5.1622 mL	12.9056 mL
	10 mM	0.2581 mL	1.2906 mL	2.5811 mL	6.4528 mL
	15 mM	0.1721 mL	0.8604 mL	1.7207 mL	4.3019 mL
	20 mM	0.1291 mL	0.6453 mL	1.2906 mL	3.2264 mL
	25 mM	0.1032 mL	0.5162 mL	1.0324 mL	2.5811 mL
	30 mM	0.0860 mL	0.4302 mL	0.8604 mL	2.1509 mL
	40 mM	0.0645 mL	0.3226 mL	0.6453 mL	1.6132 mL
	50 mM	0.0516 mL	0.2581 mL	0.5162 mL	1.2906 mL
	60 mM	0.0430 mL	0.2151 mL	0.4302 mL	1.0755 mL
	80 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8066 mL
	100 mM	0.0258 mL	0.1291 mL	0.2581 mL	0.6453 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MY-875

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) MY-875

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MY-875

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) MY-875

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MY-875 Related Classifications

Cat. No.: HY-150761